PeproMene Bio

Executive Summary

PeproMene Bio is a clinical-stage biotechnology company developing novel immune therapies targeting the B-cell Activating Factor Receptor (BAFF-R) for B-cell malignancies and immune disorders. Its lead candidate, PMB-CT01, is an autologous CAR-T cell therapy currently in Phase 1 clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. By targeting BAFF-R, which is broadly expressed on malignant B cells but not on normal hematopoietic stem cells, PMB-CT01 has the potential to offer a differentiated safety and efficacy profile compared to CD19- or CD22-directed CAR-T therapies. The company’s platform also enables development of subsequent cell therapies for autoimmune diseases, expanding its addressable market. PeproMene Bio is privately held and operates with a lean, focused approach. The Phase 1 trial of PMB-CT01 is actively enrolling at multiple sites, and initial safety and efficacy data are expected in the coming quarters. If successful, PMB-CT01 could become a best-in-class CAR-T for B-cell cancers, potentially attracting partnership interest from larger pharmaceutical companies. The company’s progress will depend on demonstration of a favorable therapeutic index and manageable toxicity. Given the early-stage nature, near-term valuation is tied to data readouts and financing events. Investors should monitor enrollment updates and interim results, as these will be critical for de-risking the platform.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 data readout for PMB-CT01 in B-cell malignancies35% success
• Q2 2026Presentation of preclinical data for next-generation BAFF-R CAR-T or autoimmune indication70% success
• TBDPotential partnership or licensing deal for PMB-CT01 in a specific geography or indication20% success